Cure8 research brief
The paper identifies a specific bacterial metabolite-receptor pathway (succinic acid → SUCNR1 → NF-κB) by which Fusobacterium nucleatum may worsen intestinal inflammation, suggesting new targets for IBD research and therapies.
Researchers (microbiome, immunology), clinicians treating IBD, and patients interested in microbiome-related causes and emerging therapeutic targets.
The researchers combined human fecal/mucosal samples, metabolomics, mouse colitis models, bacterial genetics, and cell assays. They report that F. nucleatum raises intestinal succinic acid, upregulates SUCNR1 on macrophages, activates NF-κB, and drives pro-inflammatory macrophage changes that worsen epithelial injury and colitis. A genetically modified F.
nucleatum strain that cannot produce succinic acid had less ability to trigger these effects, and adding succinic acid back restored them. Blocking SUCNR1 or NF-κB reduced the macrophage inflammatory response in experimental models. These findings point to the F.
nucleatum–succinic acid–SUCNR1–NF-κB axis as a potential therapeutic target, but the work is mechanistic and based on preclinical and translational experiments, not a clinical trial.
Findings are grounded in mechanistic experiments using human samples, animal colitis models, and bacterial genetics. This is not a clinical trial; therapeutic implications remain speculative until tested in humans.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China under Grant - 82370542; National Key R&D Program of China under Grant - 2023YFB3906600; Hubei Provincial Health Science and Technology Project - WJ2025M051
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
